Abstract
Pituitary tumor transforming gene (PTTG1) was isolated from rat pituitary tumor cells, and subsequently identified as a securin protein as well as a transcription factor. We show here a global transcriptional effect of PTTG1 in human choriocarcinoma JEG-3 cells by simultaneously assessing 20 000 gene promoters using chromatin immunoprecipitation (ChIP)-on-Chip experiments. Seven hundred and forty-six gene promoters (P<0.001) were found enriched, with functions relating to cell cycle, metabolic control and signal transduction. Significant interaction between PTTG1 and Sp1 (P<0.000001) was found by transcriptional pattern analysis of ChIP data and further confirmed by immunoprecipitation and pull-down assays. PTTG1 acts coordinately with Sp1 to induce cyclin D3 expression ∼threefold, and promotes G1/S-phase transition independently of p21. PTTG1 deletion was also protective for anchorage-independent cell colony formation. The results show that PTTG1 exhibits properties of a global transcription factor, and specifically modulates the G1/S-phase transition by interacting with Sp1. This novel signaling pathway may be required for PTTG1 transforming activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ChIP:
-
chromatin immunoprecipitation
- MEF:
-
mouse embryo fibroblast
- PTTG:
-
pituitary tumor transforming gene
References
Abdelrahim M, Samudio I, Smith III R, Burghardt R, Safe S . (2002). Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 277: 28815–28822.
Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F et al. (2002). Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 32: 306–311.
Boelaert K, Tannahill LA, Bulmer JN, Kachilele S, Chan SY, Kim D et al. (2003). A potential role for PTTG/securin in the developing human fetal brain. FASEB J 17: 1631–1639.
Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S . (2005). Pituitary hypoplasia in Pttg−/− mice is protective for Rb+/− pituitary tumorigenesis. Mol Endocrinol 19: 2371–2379.
Chien W, Pei L . (2000). A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. J Biol Chem 275: 19422–19427.
Clem AL, Hamid T, Kakar SS . (2003). Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene 322: 113–121.
Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M et al. (1998). hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17: 2187–2193.
Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD . (2002). Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 21: 1485–1492.
Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S . (1999). Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5: 1317–1321.
Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S . (2000). Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355: 716–719.
Honda S, Hayashi M, Kobayashi Y, Ishikawa Y, Nakagawa K, Tsuchiya E . (2003). A role for the pituitary tumor-transforming gene in the genesis and progression of non-small cell lung carcinomas. Anticancer Res 23: 3775–3782.
Khan S, Abdelrahim M, Samudio I, Safe S . (2003). Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. Endocrinology 144: 2325–2335.
Li Z, Van CS, Qu C, Cavenee WK, Zhang MQ, Ren B . (2003). A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 100: 8164–8169.
McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S et al. (2003). Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxford) 58: 141–150.
Pei L . (2000). Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J Biol Chem 275: 31191–31198.
Pei L . (2001). Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 276: 8484–8491.
Pei L, Melmed S . (1997). Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433–441.
Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I et al. (2000). Genome-wide location and function of DNA binding proteins. Science 290: 2306–2309.
Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K et al. (1996). Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem, 271. 28220–28228.
Saez C, Japon MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M et al. (1999). hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18: 5473–5476.
Safe S, Abdelrahim M . (2005). Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438–2448.
Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M . (2004). PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 13: 80–81.
Tarabykin V, Britanova O, Fradkov A, Voss A, Katz LS, Lukyanov S et al. (2000). Expression of PTTG and prc1 genes during telencephalic neurogenesis. Mech Dev 92: 301–304.
Wang Z, Melmed S . (2000). Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem 275: 7459–7461.
Wang Z, Moro E, Kovacs K, Yu R, Melmed S . (2003). Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci USA 100: 3428–3432.
Wang Z, Yu R, Melmed S . (2001). Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 15: 1870–1879.
Wang Z, Zhang Y, Lu J, Sun S, Ravid K . (1999). Mpl ligand enhances the transcription of the cyclin D3 gene: a potential role for Sp1 transcription factor. Blood 93: 4208–4221.
Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S . (2000). Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol 14: 1137–1146.
Zou H, McGarry TJ, Bernal T, Kirschner MW . (1999). Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285: 418–422.
Acknowledgements
p21−/− HCT116 cells were kindly provided by Dr Bert Vogelstein, Johns Hopkins University. Mouse embryos were kindly provided by Vera Chesnokova. Retroviral plasmids pBabe-ras, pWZL-E1A, pWZL-Myc and pWZL-T-Ag were from Dr Pandolfi, Memorial Sloan-Kettering Cancer Center. This work was supported by NIH Grant CA 75979 (SM) and The Doris Factor Molecular Endocrinology Laboratory.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Tong, Y., Tan, Y., Zhou, C. et al. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 26, 5596–5605 (2007). https://doi.org/10.1038/sj.onc.1210339
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210339